News & Media

Media Coverage; News and Events

Covid-19 News

Media Coverage

Press Releases

News

Covid-19 News

Two New Tests Could Lower the Coronavirus Mortality Rate by Improving Treatment for Severely Ill COVID-19 Patients

Researchers find two tests to analyse disease severity in Covid-19 patients

Inflammatory Biomarker Tests for Guiding COVID-19 Treatment

Meet the Israeli Tech Companies Fighting COVID-19 Head-On

Israeli Startups Join The Fight Against Coronavirus

MeMed's co-founder and CEO, Dr. Eran Eden on the BioBoss Podcast

OurCrowd Portfolio Companies Pivot to Tackle Coronavirus Pandemic

MeMed to predict which COVID-19 patients will worsen

Israeli firm advances diagnostic solutions for Covid-19

MeMed Receives CE Mark for Diagnostic Platform & Infection Assay

Test aiming to provide better treatment decisions receives CE mark

MeMed Ramping Up Commercialization Efforts Following Regulatory Approvals

MeMed Receives CE for Advanced Diagnostic Test

MeMed secures CE mark for new point of need blood test

MeMed Receives CE-IVD Mark for Infectious Disease Test

MeMed Receives Regulatory Green Light for Test

Study: MeMed's blood test distinguishes between bacterial, viral infections in children

ISRAEL21C: Israel races to find solutions for coronavirus

Interview with Eran Eden, MeMed's CEO

MeMed Named "Technology Pioneer" by World Economic Forum

US DoD Commits Additional Funds to MeMed's Innovative Bacterial Versus Viral Test

The journey towards a disruptive blood test that can help address the threat of antibiotic resistance

Frost__Sullivan_Recognizes_MeMed-f62568d

Frost & Sullivan Recognizes MeMed with European Technology Leadership Award

Rapid blood test to 'cut antibiotic use'

MeMed raises $70M for immune system-based infection diagnostics

Israeli Firm, US Department Of Defense To Fight Infectious Disease Together

MeMed Publishes New Data on Infectious Disease Dx, Plans 2018 Launch of POC Test

MeMed swiftly diagnoses if a disease is viral or bacterial

Towards a world without antibiotics

MeMed raises $70M

New study shows MeMed's blood test accurately distinguishes bacterial and viral infections

Novel Assay Distinguishes Bacterial From Viral Infection in Kids

Infectious Disease Detective

MeMed Using $70M Funding Round to Develop Infection Test and POC Platform

The ultimate goal is to right-size antibiotic use

Israeli infection diagnostic start-up wins $9.2M funding boost

MeMed has received a contract from the Defense Threat Reduction Agency

MeMed Wins $4.1M DOD Grant toward Manufacturing of POC Platform

Viruses from Mars, bacteria from Venus

MeMed Rolling Out Proteomic Test to Distinguish Between Bacterial, Viral Infections

MeMed Wins $9.2M DTRA Contract for PoC IVD to Reduce Antibiotic Misuse

MeMed Rolling Out Proteomic Test to Distinguish Between Bacterial, Viral Infections

A new blood test could stop doctors from over prescribing antibiotics

New Study Shows Superiority of MeMed's ImmunoXpert™ Over Procalcitonin, CRP, and HNL

MeMed has a rapid diagnostic that could help revolutionize the fight against drug-resistant bacteria

Riwat Lim Joins MeMed Team as Head of Commercial, Europe

January 19, 2020

Troy Boutelle Joins MeMed as Vice President of Commercial in North America and General Manager, U.S.

January 11, 2020

MeMed Appoints Industry Veteran Chris Hibberd to its Board of Directors

December 16, 2020

DiaSorin and MeMed Partner to Develop and Commercialize Novel Host Immune Response Based Diagnostic Solution

September 8, 2020

Prospective Study Finds Potential Utility of MeMed's Host Immune Technology for Personalizing Treatment of Severe COVID-19 Patients

July 23, 2020

MeMed Receives CE Mark for Two Pioneering Technologies: The MeMed BV™ Test and MeMed Key™ Point-of-Need Platform

June 2, 2020

MeMed Advances Diagnostic Solutions for COVID-19 Pandemic to Enable Enhanced Patient Management

May 25, 2020

Diagnostics Industry Veteran Dr. Frédéric Sweeney Joins MeMed as Chief Business Development Officer

Oct 29, 2019

News

MeMed to predict which COVID-19 patients will worsen

March 29, 2020

Israeli Startups Join The Fight Against Coronavirus

March 25, 2020

Meet the Israeli Tech Companies Fighting COVID-19 Head-On

March 25, 2020

OurCrowd Portfolio Companies Pivot to Tackle Coronavirus Pandemic

March 18, 2020

ISRAEL21C: Israel races to find solutions for coronavirus

February 16, 2020

Leveraging the immune response and machine learning to fight AMR

Nov 18, 2019

Is it a virus or a bacteria? Israeli solution wins €2.5M award

Nov 18, 2019

Frost & Sullivan Recognizes MeMed with 2019 European Technology Leadership Award

Jul 8, 2019

MeMed Named "Technology Pioneer" by World Economic Forum

Jul 1, 2019

US DoD Commits Additional Funds to MeMed's Innovative Bacterial Versus Viral Test

Dec 5, 2018

MeMed Raises Over $70 Million to Advance Pioneering Point-Of-Care Platform and Immune-Based Test for Distinguishing Bacterial Versus Viral Infections

Sep 21, 2018

MeMed will present recent analysis results of MeMed BV™ performance and potential utility in simple viral and viral bacterial coinfections in RSV and influenza patients.

ID week 2018 - 4/10/2018

MeMed's CTO will present recent meta-analysis results of performance and potential utility in mild upper respiratory tract infections.

ECCMID 2018 - 23/04/2018 09:00 am, Hall F

MeMed Secures Additional $4.1M Funding From the Department of Defense.

Feb 06, 2018

MeMed Completes Trilogy of Clinical Studies with More Than 2,000 Patients Validating First Ever Blood Test to Accurately Distinguish Between Bacterial and Viral Infections.

Sep 18, 2017

MeMed's CEO talk at ESPID was awarded best e-poster presentation.

ESPID 2017 e-poster

MeMed Awarded $9.2M Contract by US Department Of Defense.

19 Apr, 2017

"The Power within Me": MeMed CTO will talk about Reducing Antibiotics Misuse with Host Response-Based Diagnostics, at the International Molecular Diagnostics Europe, April 11th, Lisbon.

Listen to a podcast with Dr. Kfir Oved

MeMed is in GLOBES most promising companies list.

Full list (Hebrew)

Lancet Infectious Diseases Publishes Independent Double-Blind Study Validating MeMed's Immunoxpert™ Blood Test's Ability to Accurately Distinguish Between Bacterial and Viral Infections in Children.

Dec 21, 2016

MeMed's CEO will talk about Opportunities and Challenges in Personalized Diagnostics at the annual IATI Biomed conference, on May 25, Tel-Aviv, Israel.

IATI Biomed 2016

€2.3 Million Award by European Commission Will Support Deployment of ImmunoXpert™ to Reduce Antibiotic Misuse in Hospitals.

Sep 08, 2016

MeMed will host a round table of leading European pediatricians at this year"s ESPID, to discuss new strategies of using host-response based diagnostics for reducing antibiotic misuse

ESPID 2016

MeMed Joins the CDC's Initiative for Addressing Antibiotic Resistance.

Nov 16, 2015

MeMed awarded €3M from the European Commission in high profile business competition.

Jul 23, 2015

MeMed's founders, Dr. Eran Eden and Dr. Kfir Oved, included in 40 under 40 list of Israeli financial daily GLOBES.

MeMed's ImmunoXpert™ assay included in SelectScience's list of top clinical microbiology innovations.

SelectScience 2015

New Clinical Study Shows MeMed's ImmunoXpert™ Blood Test Can Accurately Distinguish Between Bacterial And Viral Infections.

Mar 19, 2015

News & Media

Covid-19 News

Meet the Israeli Tech Companies Fighting COVID-19 Head-On

Israeli Startups Join The Fight Against Coronavirus

OurCrowd Portfolio Companies Pivot to Tackle Coronavirus Pandemic

MeMed to predict which COVID-19 patients will worsen

Media Coverage

Test aiming to provide better treatment decisions receives CE mark

MeMed Ramping Up Commercialization Efforts Following Regulatory Approvals

MeMed Receives CE for Advanced Diagnostic Test

MeMed Receives CE-IVD Mark for Infectious Disease Test

MeMed Receives Regulatory Green Light for Test

MeMed Named "Technology Pioneer" by World Economic Forum

US DoD Commits Additional Funds to MeMed's Innovative Bacterial Versus Viral Test

The journey towards a disruptive blood test that can help address the threat of antibiotic resistance

Rapid blood test to 'cut antibiotic use'

MeMed raises $70M for immune system-based infection diagnostics

MeMed Publishes New Data on Infectious Disease Dx, Plans 2018 Launch of POC Test

MeMed swiftly diagnoses if a disease is viral or bacterial

MeMed raises $70M

New study shows MeMed's blood test accurately distinguishes bacterial and viral infections

Infectious Disease Detective

MeMed Using $70M Funding Round to Develop Infection Test and POC Platform

Israeli infection diagnostic start-up wins $9.2M funding boost

MeMed has received a contract from the Defense Threat Reduction Agency

Viruses from Mars, bacteria from Venus

MeMed Rolling Out Proteomic Test to Distinguish Between Bacterial, Viral Infections

MeMed Wins $9.2M DTRA Contract for PoC IVD to Reduce Antibiotic Misuse

A new blood test could stop doctors from over prescribing antibiotics

New Study Shows Superiority of MeMed's ImmunoXpert™ Over Procalcitonin, CRP, and HNL

Press Releases

January 19, 2020

January 11, 2020

December 16, 2020

September 8, 2020

July 23, 2020

June 2, 2020

May 25, 2020

Oct 29, 2019

News

March 29, 2020

March 25, 2020

March 25, 2020

March 18, 2020

February 16, 2020

Nov 18, 2019

Nov 18, 2019

Jul 8, 2019

Jul 1, 2019

Dec 5, 2018

Sep 21, 2018

ID week 2018 - 4/10/2018

ECCMID 2018 - 23/04/2018 09:00 am, Hall F

Feb 06, 2018

Sep 18, 2017

ESPID 2017 e-poster

19 Apr, 2017

Listen to a podcast with Dr. Kfir Oved

Full list (Hebrew)

Dec 21, 2016

MeMed's CEO will talk about Opportunities and Challenges in Personalized Diagnostics at the annual IATI Biomed conference, on May 25, Tel-Aviv, Israel.

IATI Biomed 2016

Sep 08, 2016

MeMed will host a round table of leading European pediatricians at this year"s ESPID, to discuss new strategies of using host-response based diagnostics for reducing antibiotic misuse

ESPID 2016

MeMed Joins the CDC's Initiative for Addressing Antibiotic Resistance.

Nov 16, 2015

Jul 23, 2015

SelectScience 2015

Mar 19, 2015

MeMed 2018 www.me-med.com (C) All rights reserved | Privacy Policy | Terms & Conditions

MeMed 2018 (C) All rights reserved | Privacy Policy | Terms & Conditions